Drug Research
Collaboration to identify biomarkers that predict therapeutic response
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify biomarkers that predict therapeutic response and the incidence of immune-related adverse events (irAEs) in urothelial carcinoma patients...
Articles
Is the market now DSCSA ready?
Roundtable questionsIn November 2017, the pharma industry was granted an extension of the Drug Supply Chain Security Act (DSCSA) enforcement date to November 2018. Regulators told the market that they would not actively enforce the new serialization requirements until...
Drug Research
Oxford Genetics extends its CRISPR Gene Editing Technology License Agreement from ERS Genomics to support its growth internationally
Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, and ERS Genomics have extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which...
Articles
Quicker, More Accurate Diagnoses for Dangerous Diseases and Genetic Disorders
Standfirst:There is growing awareness of the valuable role that diagnostics can play, both in the early identification and treatment of dangerous or infectious diseases as well as genetic disorders.
The early and accurate identification of one’s predisposition to cancer, sexually...
Articles
Looking Towards the Future: Worldwide Biosimilar Uptake and Pricing
What is a biosimilar?
Whereas generic drugs are identical copycats of small-molecule chemical products, biosimilars are only similar to biologic products; innately more complex than chemical products, biologics are large-molecule, organic drugs, subject to natural variability and vulnerability due to...
Articles
Risking Addiction for Relief: Is There a Better Alternative to Opioids?
Every day, the United States loses 116 lives to the opioid epidemic.(1) Pharmacists are asking what can be done to combat the opioid epidemic and treat pain effectively.
In the ever-changing healthcare environment, minimizing pain is a top priority, but...
Drug Research
Process innovation needs to be undertaken in early R&D phase predicts ADC Bio
ADC Biotechnology (ADC Bio) predicts that the next crucial phase of innovation to optimise and streamline production processes of ADCs will be designed at the clinical development stage by specialist, ADC focused service providers. At present,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
